angiotensin ii has been researched along with dapagliflozin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, NG; Arad, M; Aravot, D; Arow, M; Freimark, D; Hochhauser, E; Kornowski, R; Nudelman, V; Shainberg, A; Waldman, M; Yadin, D | 1 |
| Boogerd, CJ; de Boer, RA; Dokter, MM; Lam, CSP; Markousis-Mavrogenis, G; Meems, LMG; Schouten, EM; Silljé, HHW; Voors, AA; Westenbrink, BD; Withaar, C | 1 |
| Chai, D; Chen, X; Chu, Y; Du, H; Lin, J; Lin, X; Liu, J; Ma, K; Ruan, Q; Xie, H; Xu, C; Zeng, J; Zhang, H; Zhang, Y | 1 |
| Li, L; Lu, Z; Yang, J; Zheng, X; Zhou, H | 1 |
4 other study(ies) available for angiotensin ii and dapagliflozin
| Article | Year |
|---|---|
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Topics: Angiotensin II; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Calcium Channels, L-Type; Calcium Signaling; Cells, Cultured; Diabetes Mellitus; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Glucosides; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Rats, Sprague-Dawley; Sodium-Calcium Exchanger; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 1; Ventricular Function, Left | 2020 |
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Topics: Angiotensin II; Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Female; Fibrosis; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure, Diastolic; Hypertrophy, Left Ventricular; Incretins; Liraglutide; Mice, Inbred C57BL; Myocardium; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Topics: Angiotensin II; Animals; Antifibrotic Agents; Benzhydryl Compounds; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Glucosides; Hypertrophy, Left Ventricular; Male; Myocardium; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sodium-Glucose Transporter 2 Inhibitors; Transforming Growth Factor beta1; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Mice; Myocytes, Cardiac; Signal Transduction; Sirtuin 1; Stroke Volume; Ventricular Function, Left | 2023 |